



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/00, 7/00, C12N 15/10, 15/11, 15/12	A1	(11) International Publication Number: WO 99/09061 (43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/US98/17469 (22) International Filing Date: 21 August 1998 (21.08.98) (30) Priority Data: 08/916,041 21 August 1997 (21.08.97) US 09/137,226 20 August 1998 (20.08.98) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 111 Locust Street #41, Woburn, MA 01801 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). (74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Street, Cambridge, MA 02140 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: SECRETED PROTEINS (57) Abstract Novel proteins are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SECRETED PROTEINS

5 This application is a continuation-in-part of application Ser. No. 60/092,114 (converted to a provisional application from non-provisional application Ser. No. 08/916,041), filed August 21, 1997, which is incorporated by reference herein.

FIELD OF THE INVENTION

10 The present invention provides novel proteins , along with therapeutic, diagnostic and research utilities for these proteins.

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines,
15 such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression
20 cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by
25 virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins that the present invention is directed.

30

35

40

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 389 to nucleotide 694;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone am207_1i deposited under accession
10 number ATCC 98510;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510;
- (e) a polynucleotide comprising the nucleotide sequence of a mature
15 protein coding sequence of clone am207_1i deposited under accession number ATCC 98510;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a protein comprising the amino acid
sequence of SEQ ID NO:2;
- 20 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; and
- 25 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 389 to nucleotide 694; the nucleotide sequence of the full-length protein coding sequence of clone am207_1i deposited under accession number ATCC
30 98510; or the nucleotide sequence of a mature protein coding sequence of clone am207_1i deposited under accession number ATCC 98510. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
 - 5 (b) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins. Preferably such
- 10 protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino
- 15 SEQ ID NO:2, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of:

- 20 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 122 to nucleotide 685;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 179 to nucleotide 685;
- 25 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone am910_1i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510;
- 30 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone am910_1i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510;

- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:5;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:5;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:4 from nucleotide 122 to nucleotide 685; the nucleotide sequence of SEQ ID NO:4 from nucleotide 179 to nucleotide 685; the nucleotide sequence of the full-length protein coding sequence of clone am910_1i deposited under accession number ATCC 98510; or the nucleotide sequence of a mature protein coding sequence of clone am910_1i deposited under accession number ATCC 98510. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510. In yet other preferred embodiments, such polynucleotide encodes a protein comprising the amino acid sequence of SEQ ID NO:5 from amino acid 85 to amino acid 139. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:5, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:5.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:5;
- (b) the amino acid sequence of SEQ ID NO:5 from amino acid 85 to amino acid 139;
- (c) fragments of the amino acid sequence of SEQ ID NO:5 comprising eight consecutive amino acids of SEQ ID NO:5; and

(d) the amino acid sequence encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510; the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:5 or the amino acid sequence of SEQ ID NO:5 from amino acid 85 to amino acid 139. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:5, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5, the fragment comprising the amino acid sequence from amino acid 89 to amino acid 98 of SEQ ID NO:5.

In one embodiment, the present invention provides a composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 84 to nucleotide 269;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 144 to nucleotide 269;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ar54_1i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ar54_1i deposited under accession number ATCC 98510;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ar54_1i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ar54_1i deposited under accession number ATCC 98510;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:7;

- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

5 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:6 from nucleotide 84 to nucleotide 269; the nucleotide sequence of SEQ ID NO:6 from nucleotide 144 to nucleotide 269; the nucleotide sequence of the full-length protein coding sequence of clone ar54_1i deposited under accession number ATCC 98510; or the
10 nucleotide sequence of a mature protein coding sequence of clone ar54_1i deposited under accession number ATCC 98510. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ar54_1i deposited under accession number ATCC 98510.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
15 consisting of:

- (a) the amino acid sequence of SEQ ID NO:7;
 - (b) fragments of the amino acid sequence of SEQ ID NO:7 comprising eight consecutive amino acids of SEQ ID NO:7; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone
20 ar54_1i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:7. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity, the fragment preferably
25 comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:7, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7, the fragment comprising the amino acid sequence from amino acid 26 to amino acid 35 of SEQ ID NO:7.

In one embodiment, the present invention provides a composition comprising an
30 isolated protein encoded by a polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 32 to nucleotide 1300;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 884 to nucleotide 1300;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone L200_1i deposited under accession number ATCC 98510;
- 5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone L200_1i deposited under accession number ATCC 98510;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone L200_1i deposited under accession number ATCC 98510;
- 10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone L200_1i deposited under accession number ATCC 98510;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
- 15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:9;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- 20 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:8 from nucleotide 32 to nucleotide 1300; the nucleotide sequence of SEQ ID NO:8 from nucleotide 884 to nucleotide 1300; the nucleotide sequence of the full-length protein coding sequence of clone L200_1i deposited under accession number ATCC 98510; or the nucleotide sequence of a mature protein coding sequence of clone L200_1i deposited under accession number ATCC 98510. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone L200_1i deposited under accession number ATCC 98510. In yet other preferred

25

30

embodiments, such polynucleotide encodes a protein comprising the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 144. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty)

consecutive amino acids of SEQ ID NO:9, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:9.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:9;
 - (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to
10 amino acid 144;
 - (c) fragments of the amino acid sequence of SEQ ID NO:9 comprising eight consecutive amino acids of SEQ ID NO:9; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone
L200_1i deposited under accession number ATCC 98510;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:9 or the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 144. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity, the fragment preferably comprising
20 eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:9, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9, the fragment comprising the amino acid sequence from amino acid 206 to amino acid 215 of SEQ ID NO:9.

In one embodiment, the present invention provides a composition comprising an
25 isolated protein encoded by a polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 85 to nucleotide 1059;
- 30 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 151 to nucleotide 1059;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone wa129_2i deposited under accession number ATCC 98510;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone wa129_2i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:11;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:11;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:10 from nucleotide 85 to nucleotide 1059; the nucleotide sequence of SEQ ID NO:10 from nucleotide 151 to nucleotide 1059; the nucleotide sequence of the full-length protein coding sequence of clone wa129_2i deposited under accession number ATCC 98510; or the nucleotide sequence of a mature protein coding sequence of clone wa129_2i deposited under accession number ATCC 98510. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:11;
- (b) fragments of the amino acid sequence of SEQ ID NO:11 comprising eight consecutive amino acids of SEQ ID NO:11; and
- (c) the amino acid sequence encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:11. In further preferred

embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:11, or a protein comprising a fragment of the amino acid sequence of
5 SEQ ID NO:11, the fragment comprising the amino acid sequence from amino acid 157 to amino acid 166 of SEQ ID NO:.

In one embodiment, the present invention provides a composition comprising an isolated protein encoded by a polynucleotide selected from the group consisting of:

- 10 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12 from nucleotide 128 to nucleotide 643;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12 from nucleotide 197 to nucleotide 643;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone wa154_3i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510;
- 20 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone wa154_3i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:13;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:13;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:12 from nucleotide 128 to nucleotide 643; the nucleotide sequence of SEQ ID NO:12 from nucleotide 197 to nucleotide 643; the nucleotide sequence of the full-length protein coding sequence of clone wa154_3i deposited under accession number ATCC 98510; or
5 the nucleotide sequence of a mature protein coding sequence of clone wa154_3i deposited under accession number ATCC 98510. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510. In yet other preferred embodiments, such polynucleotide encodes a protein comprising the amino acid sequence
10 of SEQ ID NO:13 from amino acid 37 to amino acid 77. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:13, or a polynucleotide encoding a protein
15 comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID NO:13.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
20 consisting of:

- (a) the amino acid sequence of SEQ ID NO:13;
- (b) the amino acid sequence of SEQ ID NO:13 from amino acid 37 to amino acid 77;
- (c) fragments of the amino acid sequence of SEQ ID NO:13 comprising
25 eight consecutive amino acids of SEQ ID NO:13; and
- (d) the amino acid sequence encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:13 or the amino acid sequence
30 of SEQ ID NO:13 from amino acid 37 to amino acid 77. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:13, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13,

the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID NO:13.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION

ISOLATED PROTEINS

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Protein "am207_1i"

One protein of the present invention has been identified as protein "am207_1i". A partial cDNA clone encoding am207_1i was first isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. The nucleotide sequence of such partial cDNA was determined and searched against the GenBank and GeneSeq databases using BLASTN/BLASTX and FASTA search protocols, and later the full-length clone sequence was determined and searched as well. The search revealed at least some similarity to sequences identified as D55856 (Human fetal brain cDNA 5'-end GEN-404C03, mRNA sequence), R52804 (yg99g12.r1 Homo sapiens cDNA clone 41757 5'), R96245 (yq36a02.r1 Homo sapiens cDNA clone 197834 5'), and T47661 (cDNA encoding small CCN-like growth factor). The predicted amino acid sequence disclosed herein for am207_1i was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted am207_1i protein demonstrated at least some similarity to sequences identified as W09408 (Human small CCN-like growth factor).

The human cDNA clone corresponding to the EST database entry was ordered from Genome Systems, Inc., St. Louis, Mo, a distributor of the I.M.A.G.E. Consortium library. The clone received from the distributor was examined and determined to be a full-length clone, including a 5' end and 3' UTR (including a polyA tail). This full-length clone is also referred to herein as "am207_1i".

Applicants' methods identified clone am207_1i as encoding a secreted protein.

The nucleotide sequence of the 5' portion of am207_1i as presently determined is reported in SEQ ID NO:1. What applicants believe is the proper reading frame and the predicted amino acid sequence of the am207_1i protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Additional nucleotide sequence from the 3' portion of am207_1i, including the polyA tail, is reported in SEQ ID NO:3.

Protein "am910_1i"

One protein of the present invention has been identified as protein "am910_1i". A partial cDNA clone encoding am910_1i was first isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins

(see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. The nucleotide sequence of such partial cDNA was determined and searched against the GenBank and GeneSeq databases using BLASTN/BLASTX and FASTA search protocols, and later the full-length clone sequence was determined and searched as well. The search revealed at least some similarity to sequences identified as AA011070 (ze21b12.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 359615 5' similar to WP:F22B5.10 CE02196), AA186745 (zp73g04.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 625878 3'), AF070626 (Homo sapiens clone 24483 unknown mRNA, partial cds), H18735 (ym45d07.r1 Homo sapiens cDNA clone 51259 5'), Q76763 (Human genome fragment), T30877 (EST24359 Homo sapiens cDNA 5'), and T68411 (yc42a06.s1 Homo sapiens cDNA clone 83314 3'). The predicted amino acid sequence disclosed herein for am910_1i was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted am910_1i protein demonstrated at least some similarity to sequences identified as AF070626 (unknown [Homo sapiens]) and Z50044 (F22B5.10 [Caenorhabditis elegans]).

The human cDNA clone corresponding to the EST database entry was ordered from Genome Systems, Inc., St. Louis, Mo, a distributor of the I.M.A.G.E. Consortium library. The clone received from the distributor was examined and determined to be a full-length clone, including a 5' end and 3' UTR (including a polyA tail). This full-length clone is also referred to herein as "am910_1i".

Applicants' methods identified clone am910_1i as encoding a secreted protein.

The nucleotide sequence of am910_1i as presently determined is reported in SEQ ID NO:4. What applicants believe is the proper reading frame and the predicted amino acid sequence of the am910_1i protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:5. Amino acids 7 to 19 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain. The TopPredII computer program predicts an additional potential transmembrane domain within the am910_1i protein sequence centered around amino acid 99 of SEQ ID NO:5.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone am910_1i should be approximately 800 bp.

Protein "ar54_1i"

One protein of the present invention has been identified as protein "ar54_1i". A partial cDNA clone encoding ar54_1i was first isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. The nucleotide sequence of such partial cDNA was determined and searched against the GenBank and GeneSeq databases using BLASTN/BLASTX and FASTA search protocols, and later the full-length clone sequence was determined and searched as well. The search revealed at least some similarity to sequences identified as AA325647 (EST28665 Cerebellum II Homo sapiens cDNA 5' end), AA524244 (ng34a04.s1 NCI_CGAP_Co3 Homo sapiens cDNA clone 936654), C04826 (Human Heart cDNA, clone 3NHC4071), H14110 (ym62b02.r1 Homo sapiens cDNA clone 163467 5'), H17526 (ym41d07.s1 Homo sapiens cDNA clone 50831 3'), H29060 (ym59h04.s1 Homo sapiens cDNA clone 52921 3'), H56455 (yq98h11.r1 Homo sapiens cDNA clone 203877 5'), and R60248 (yh03a03.r1 Homo sapiens cDNA clone 41920 5').

The human cDNA clone corresponding to the EST database entry was ordered from Genome Systems, Inc., St. Louis, Mo, a distributor of the I.M.A.G.E. Consortium library. The clone received from the distributor was examined and determined to be a full-length clone, including a 5' end and 3' UTR (including a polyA tail). This full-length clone is also referred to herein as "ar54_1i".

Applicants' methods identified clone ar54_1i as encoding a secreted protein.

The nucleotide sequence of ar54_1i as presently determined is reported in SEQ ID NO:6. What applicants believe is the proper reading frame and the predicted amino acid sequence of the ar54_1i protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:7. Amino acids 8 to 20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21, or are a transmembrane domain. The TopPredII computer program predicts an additional potential transmembrane domain within the ar54_1i protein sequence centered around amino acid 33 of SEQ ID NO:7.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ar54_1i should be approximately 1300 bp.

Protein "L200_1i"

One protein of the present invention has been identified as protein "L200_1i". A partial cDNA clone encoding L200_1i was first isolated from a Mouse adult thymus cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. The nucleotide sequence of such partial cDNA was determined and searched against the GenBank and GeneSeq databases using BLASTN/BLASTX and FASTA search protocols, and later the full-length clone sequence was determined and searched as well. The search revealed at least some similarity to sequences identified as AA061905 (mj92f05.r1 Soares mouse p3NMF19.5 Mus musculus cDNA clone 483585 5' similar to WP T12A7.1 CE06433), R18663 (yf97g05.r1 Homo sapiens cDNA clone 30629 5'), T85333 (yd82a01.s1 Homo sapiens cDNA clone 114696 3'), U83246 (Human copine I mRNA, complete cds), W74724 (zd56a01.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 344616 3'), and Z45080 (H. sapiens partial cDNA sequence; clone c-2gc02). The predicted amino acid sequence disclosed herein for L200_1i was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted L200_1i protein demonstrated at least some similarity to sequences identified as U83246 (copine I [Homo sapiens]).

The human cDNA clone corresponding to the EST database entry was ordered from Genome Systems, Inc., St. Louis, Mo, a distributor of the I.M.A.G.E. Consortium library. The clone received from the distributor was examined and determined to be a full-length clone, including a 5' end and 3' UTR (including a polyA tail). This full-length clone is also referred to herein as "L200_1i".

Applicants' methods identified clone L200_1i as encoding a secreted protein.

The nucleotide sequence of L200_1i as presently determined is reported in SEQ ID NO:8. What applicants believe is the proper reading frame and the predicted amino acid sequence of the L200_1i protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:9. Amino acids 272 to 284 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 285, or are a transmembrane domain. The TopPredII computer program predicts four additional potential transmembrane domains within the L200_1i protein sequence, centered around amino acids 180, 255, 355, and 395 of SEQ ID NO:9, respectively.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone L200_1i should be approximately 1330 bp.

Protein "wa129_2i"

5 One protein of the present invention has been identified as protein "wa129_2i". A partial cDNA clone encoding wa129_2i was first isolated from a *Xenopus* embryo cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded
10 protein. The nucleotide sequence of such partial cDNA was determined and searched against the GenBank and GeneSeq databases using BLASTN/BLASTX and FASTA search protocols, and later the full-length clone sequence was determined and searched as well. The search revealed at least some similarity to sequences identified as AA058865 (zf65f09.s1 Soares retina N2b4HR Homo sapiens cDNA clone 381833 3' similar to contains
15 Alu repetitive element), H18848 (ym45f09.r1 Homo sapiens cDNA clone 51061 5' similar to SP A45054 A45054 FZ-1 PUTATIVE INTERCELLULAR SIGNAL TRANSDUCER OR TRANSMITTER), N71244 (yw37e11.r1 Homo sapiens cDNA clone 254444 5'), T12460 (Ovine adenovirus genome), U68057 (Human frezzled (fre) mRNA, complete cds), U68059 (*Xenopus laevis* frezzled (fre) mRNA, complete cds), and U91903 (Human Fritz mRNA,
20 complete cds). The predicted amino acid sequence disclosed herein for wa129_2i was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted wa129_2i protein demonstrated at least some similarity to sequences identified as U68057 (frezled [Homo sapiens]), U68059 (frezled [*Xenopus laevis*]), and X54648 (frizzled (clone BE2) gene product [*Drosophila melanogaster*]).
25

The human cDNA clone corresponding to the EST database entry was ordered from Genome Systems, Inc., St. Louis, Mo, a distributor of the I.M.A.G.E. Consortium library. The clone received from the distributor was examined and determined to be a full-length clone, including a 5' end and 3' UTR (including a polyA tail). This full-length
30 clone is also referred to herein as "wa129_2i".

Applicants' methods identified clone wa129_2i as encoding a secreted protein.

The nucleotide sequence of wa129_2i as presently determined is reported in SEQ ID NO:10. What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO:11. Amino

acids 10 to 22 of SEQ ID NO: are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23, or are a transmembrane domain. The TopPredII computer program predicts an additional potential transmembrane domain within the wa129_2i protein sequence centered around amino acid 90 of SEQ ID NO:11.

Protein "wa154_3i"

One protein of the present invention has been identified as protein "wa154_3i". A partial cDNA clone encoding wa154_3i was first isolated from a Xenopus embryo cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. The nucleotide sequence of such partial cDNA was determined and searched against the GenBank and GeneSeq databases using BLASTN/BLASTX and FASTA search protocols, and later the full-length clone sequence was determined and searched. The search revealed at least some similarity to sequences identified as AA194085 (zr37a05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 665552 5'), T31098 (Papillomavirus E2 binding protein E2-BP SD23 cDNA), T81278 (yd06f07.r1 Homo sapiens cDNA clone 24952 5'), and W49086 (md26e12.r1 Life Tech mouse brain Mus musculus cDNA clone 369550 5'). The predicted amino acid sequence disclosed herein for wa154_3i was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted wa154_3i protein demonstrated at least some similarity to sequences identified as U76752 (putative secreted protein XAG [Xenopus laevis]), W00499 (Papillomavirus E2 binding protein E2-BP SD-23), and X14959 (Spinach mRNA for thioredoxin f. [Spinacia oleracea]).

The human cDNA clone corresponding to the EST database entry was ordered from Genome Systems, Inc., St. Louis, Mo, a distributor of the I.M.A.G.E. Consortium library. The clone received from the distributor was examined and determined to be a full-length clone, including a 5' end and 3' UTR (including a polyA tail). This full-length clone is also referred to herein as "wa154_3i".

Applicants' methods identified clone wa154_3i as encoding a secreted protein.

The nucleotide sequence of wa154_3i as presently determined is reported in SEQ ID NO:12. What applicants believe is the proper reading frame and the predicted amino

acid sequence of the wa154_3i protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:13. Amino acids 11 to 23 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24, or are a transmembrane domain. The predicted wa154_3i protein demonstrates at least some
5 similarity to Protein Disulfide Isomerase (PDI): it has PDI's thioredoxin active site (Cys-Gly-Ala-Cys) at amino acid 66 to amino acid 69 of SEQ ID NO:13, and has strong sequence similarity in the region of the active site (beginning approximately at amino acid 58 of SEQ ID NO:13). The predicted wa154_3i protein has a strong signal sequence as expected for a PDI-like protein since these proteins are exported into the ER lumen.
10 Further, the predicted wa154_3i protein has a putative ER retention signal (EDEL) at the C-terminus: the classic retention signal is KDEL. Therefore wa154_3i is likely to be a PDI-related protein and retained in the endoplasmic reticulum.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone wa154_3i should be approximately 1469 bp.

15

Deposit of Clones

Clones am207_1i, am910_1i, ar54_1i, L200_1i, wa129_2i, and wa154_3i were deposited on August 21, 1997 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under
20 the Budapest Treaty and were given the accession number ATCC 98510, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

25 Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector
30 ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped"

(i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the
5 vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences
10 provided herein, or from a combination of those sequences.

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-
15 diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- 20 (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ - ^{32}P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated
25 label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4×10^6 dpm/pmol.

The bacterial culture containing the pool of full-length clones should preferably
30 be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 $\mu\text{g}/\text{ml}$. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated

colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the
5 colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at
10 a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The
15 filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis,
20 hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, Bio/Technology 10, 773-778 (1992) and in R.S. McDowell, *et al.*, J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated
25 herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion
30 could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence

listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be
5 determinable from the amino acid sequence of the full-length form.

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and
10 transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence
15 identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more
20 (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

Species homologues of the disclosed proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a
25 different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at
30 least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues

may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed proteins; that is, naturally-occurring alternative forms of the isolated proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The isolated polynucleotide encoding the protein of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined

herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

5 A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells,
10 mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial
15 strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or
20 enzymatic methods.

 The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from,
25 e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

30 The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column

containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity
5 chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially
10 available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus
15 purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the
20 protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational
25 characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications
5 of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art
10 (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art
15 given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

The proteins of the present invention are expected to exhibit one or more of the
20 uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

25

Research Uses and Utilities

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a
30 reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially

binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding
5 interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular
10 Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

15 Proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such
20 as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

25 A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient
30 confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

- Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

- Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

- Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies,

- E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

- A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

- Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an

immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires
5 continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing
10 agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example,
15 blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble,
20 monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this
25 matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or
30 tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac

grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed.,
5 Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate
10 activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell
15 activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of
20 human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

25 Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of
30 viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-

pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having

the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

- 5 The activity of a protein of the invention may, among other means, be measured by the following methods:

 Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates
 10 and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, *Immunologic studies in Humans*); Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Herrmann et al., *Proc. Natl. Acad. Sci. USA* 78:2488-2492,
 15 1981; Herrmann et al., *J. Immunol.* 128:1968-1974, 1982; Handa et al., *J. Immunol.* 135:1564-1572, 1985; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bowman et al., *J. Virology* 61:1992-1998; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Brown et al., *J. Immunol.* 153:3079-3092, 1994.

 Assays for T-cell-dependent immunoglobulin responses and isotype switching
 20 (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

25 Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, *In Vitro* assays for Mouse Lymphocyte Function 3.1-3.19; Chapter
 30 7, *Immunologic studies in Humans*); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988; Bertagnolli et al., *J. Immunol.* 149:3778-3783, 1992.

 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., *J. Immunol.* 134:536-544, 1995; Inaba et al., *Journal of*

Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj
 5 et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz
 10 et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and
 15 development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

20 A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines,
 25 thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent
 30 myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-

mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or
5 *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

10 Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al.,
15 Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of*
20 *Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359,
25 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland,
30 H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns,
5 incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as
10 well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal
15 disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue
20 destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in
25 circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and
30 in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or

ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal
5 tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and
10 peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's,
15 Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the
20 invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for
25 generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may
30 also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured
5 by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

10 Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

15 Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present
20 invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-
25 β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

30 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et

al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

5 A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide
10 particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

15 A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

20 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one
25 cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al.
30 APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

10 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 15 35:467-474, 1988.

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

30 The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and

Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 5 1995.

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in 10 the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat 15 inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting 20 from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major 25 roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

30 The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the

first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

5 E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to
10 their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention
15 encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue
20 in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and
25 polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the
30 cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used

to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides
5 encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

10 Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or
15 tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

20 Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height,
25 weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein,
30 carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic

lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen
5 in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

10 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term
15 "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11,
20 IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention,
25 or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

30 A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be

administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred

pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The
5 pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.
10 Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not
15 increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μ g to about 100 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1 μ g to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous
20 therapy using the pharmaceutical composition of the present invention.
25

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the
30 carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal

antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting
5 and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When
10 administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also
15 optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the
20 developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular
25 application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins
30 or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-

aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.

- 5 In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, 10 ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 15 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

20 In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

25 The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering 30 various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in

the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline
5 labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without
10 limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

15 Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated protein encoded by a polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 389 to nucleotide 694;
 - (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone am207_1i deposited under accession number ATCC 98510;
 - (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510;
 - (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone am207_1i deposited under accession number ATCC 98510;
 - (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510;
 - (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
 - (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; and
 - (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above.
2. A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
3. A protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;

- (b) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone am207_1i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins.

4. The protein of claim 3, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

5. A composition comprising the protein of claim 3 and a pharmaceutically acceptable carrier.

6. An isolated protein encoded by a polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 122 to nucleotide 685;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:4 from nucleotide 179 to nucleotide 685;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone am910_1i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone am910_1i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:5;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:5 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:5;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

7. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:5;
 - (b) the amino acid sequence of SEQ ID NO:5 from amino acid 85 to amino acid 139;
 - (c) fragments of the amino acid sequence of SEQ ID NO:5 comprising eight consecutive amino acids of SEQ ID NO:5; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone am910_1i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins.

8. An isolated protein encoded by a polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 84 to nucleotide 269;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:6 from nucleotide 144 to nucleotide 269;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ar54_1i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ar54_1i deposited under accession number ATCC 98510;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ar54_1i deposited under accession number ATCC 98510;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ar54_1i deposited under accession number ATCC 98510;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:7;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:7 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:7;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.
9. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:7;
 - (b) fragments of the amino acid sequence of SEQ ID NO:7 comprising eight consecutive amino acids of SEQ ID NO:7; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone ar54_1i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins.
10. An isolated protein encoded by a polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 32 to nucleotide 1300;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:8 from nucleotide 884 to nucleotide 1300;

- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone L200_1i deposited under accession number ATCC 98510;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone L200_1i deposited under accession number ATCC 98510;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone L200_1i deposited under accession number ATCC 98510;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone L200_1i deposited under accession number ATCC 98510;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:9;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:9 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:9;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.
11. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:9;
 - (b) the amino acid sequence of SEQ ID NO:9 from amino acid 1 to amino acid 144;
 - (c) fragments of the amino acid sequence of SEQ ID NO:9 comprising eight consecutive amino acids of SEQ ID NO:9; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone L200_1i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins.

12. An isolated protein encoded by a polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 85 to nucleotide 1059;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:10 from nucleotide 151 to nucleotide 1059;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone wa129_2i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone wa129_2i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:11;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:11 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:11;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

13. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:11;
- (b) fragments of the amino acid sequence of SEQ ID NO: comprising eight consecutive amino acids of SEQ ID NO:11; and
- (c) the amino acid sequence encoded by the cDNA insert of clone wa129_2i deposited under accession number ATCC 98510;

the protein being substantially free from other mammalian proteins.

14. An isolated protein encoded by a polynucleotide selected from the group consisting of:


- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12 from nucleotide 128 to nucleotide 643;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:12 from nucleotide 197 to nucleotide 643;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone wa154_3i deposited under accession number ATCC 98510;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone wa154_3i deposited under accession number ATCC 98510;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:13;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:13 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:13;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above.

15. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:13;
- (b) the amino acid sequence of SEQ ID NO:13 from amino acid 37 to amino acid 77;

- (c) fragments of the amino acid sequence of SEQ ID NO:13 comprising eight consecutive amino acids of SEQ ID NO:13; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone wa154_3i deposited under accession number ATCC 98510;
- the protein being substantially free from other mammalian proteins.

FIGURE 1A




Plasmid name: pED6dpc2

Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs

Plasmid size: 4529 bp

Comments/References: pNOTs is a derivative of pMT2 (Kaufman et al, 1989. Mol. Cell. Biol. 9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the ClaI site. SST cDNAs are cloned between EcoRI and NotI

SEQUENCE LISTING

<110> Jacobs, Kenneth
 McCoy, John M.
 Racie, Lisa A.
 LaVallie, Edward R.
 Evans, Cheryl
 Merberg, David
 Treacy, Maurice
 Genetics Institute, Inc.

<120> SECRETED PROTEINS

<130> 6504A

<140>

<141>

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 694

<212> DNA

<213> Homo sapiens

<400> 1

```

aagcttggca cgaggggncaa acctctatgg atatataaag ggaagcttga ggaggaattt 60
cncagttaca gtgcagaagc acaagcaaaa gaattaacca gctcttcagt caagcaaatc 120
ctctactcac catgcttcct cctgccattc atttctatct ccttcccctt gcatgcatcc 180
taatgaaaag ctgtttgggt tttaaaaatg atgccacaga aatcctttat tcacatgtgg 240
ttaaacctgt tccagcacac cccagcagca acagcacgtt gaatcaagcc agaaatgggt 300
gcaggcattt cagtaacact ggactggatc ggaacactcg ggttcaagtg ggttgccggg 360
aankgcnctc ccaccaataa catctctgat ggccagtgcg ccagcatcag ccntangaag 420
gagntgggtg gtgctggcga gtgacttgcc cctgccagtg ctcntaatt ggnttgaggg 480
aggctgtgga acaangtant ggagcaggag gagctcccag gngtggcggt gtgtcaatga 540
caaaaccngt acccagagaa tccagntgca gttccaagat ggcngcacac gcacgtacaa 600
aatcacagta gtcggtgccn gcaagtgcaa gaggtacacc cggcagcaca nngagtccag 660
tcacganttt gagagcatnt cacgtgccaa gcca                                694

```

<210> 2

<211> 102

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Ala Ser Ala Pro Ala Ser Ala Xaa Xaa Arg Xaa Trp Cys Val Leu
  1              5              10              15

Ala Ser Asp Leu Pro Leu Pro Val Leu Xaa Asn Trp Xaa Gly Gly Gly
      20              25              30

Cys Gly Thr Xaa Xaa Trp Ser Arg Arg Ser Ser Gln Xaa Trp Arg Cys
      35              40              45

Val Asn Asp Lys Thr Xaa Thr Gln Arg Ile Gln Xaa Gln Phe Gln Asp
      50              55              60

Gly Xaa Thr Arg Thr Tyr Lys Ile Thr Val Val Gly Ala Xaa Lys Cys

```

65 70 75 80

Lys Arg Tyr Thr Arg Gln His Xaa Glu Ser Ser His Xaa Phe Glu Ser

85 90 95

Xaa Ser Arg Ala Lys Pro

100

<210> 3
 <211> 243
 <212> DNA
 <213> Homo sapiens

<400> 3

atatgaaata catgtttag atatgtaaaa tgaatatttt agtctccctt atnacatata 60

tggtcatggt gaactttatc aatagtatgg atctttttta atcaataaga tgctttgtaa 120

agttgaaata agtaatactt tcttgtttaa tctgtgcaat cagaagggtg cttgaccttc 180

aattcaattg gtttctttta acaaaaataa acactgctaa aagttaaaaa aaaaaaaaaa 240

aaa 243

<210> 4
 <211> 1187
 <212> DNA
 <213> Homo sapiens

<400> 4

tgtagagatt ggtctgttac tcgggtggtg cggagtctac ggaagccgtt ttcgcttcac 60

ttttcctggc tgtagagcgc tttcccccctg gcgggtgaga gtgcagagac gaagggtgca 120

gatgagcact atgttcgcgg acactctcct catcggtttt atctctgtgt gcacggctct 180

gctcgagag ggcataacct gggctcctgt ttacaggaca gacaagtaca agagactgaa 240

ggcagaagtg gaaaaacaga gtaaaaaatt ggaaaagaag aaggaaacaa taacagagtc 300

agctggtcga caacagaaaa agaaaataga gagacaagaa gagaaactga agaataacaa 360

cagagatcta tcaatggttc gaatgaaatc catgtttgct attggctttt gttttactgc 420

cctaattgga atgttcaatt ccatatttga tggtagagt gtggcaaagc ttccttttac 480

ccctctttct tacatccaag gactgtctca tcgaaatctg ctgggagatg acaccacaga 540

ctgttccttc attttctctgt atattctctg tactatgtcg attcgacaga acattcagaa 600

gattctcggc cttgccccct cagagccgc caccaagcag gcaggtggat ttcttgcccc 660

accacctcct tctgggaagt tctcttgaac tcaagaactc tttattttct atcattcttt 720

ctagacacac acacatcaga ctggcaactg ttttgtagca agagccatag gtagccttac 780

tacttgggccc tctttctagt tttgaattat ttctaagcct tttgggtatg attagagtga 840

aaatggcagc cagcaaaact gatagtgtt ttggtcctag atgattttta tcaaataagt 900

ggattgatta gttaagttca ggtaatgtt atgtaatgaa aaacaaatag catccttctt 960

gtttcattta cataagtatt ttctgtggga cgcactctca aggcactgtg tatgccctgc 1020

aagttggctg tctatgagca tttagagatt tagaagaaaa atttagtttg ttttaacctt 1080

gtaactgttt gttttgtgtg tgtttttttt tcaagccaaa tacatgacat aagatcaata 1140

aagaggccaa attttttagct gttttatgta aaaaaaaaaa aaaaaaa 1187

<210> 5
 <211> 188
 <212> PRT
 <213> Homo sapiens

<400> 5

Met Ser Thr Met Phe Ala Asp Thr Leu Leu Ile Val Phe Ile Ser Val

1 5 10 15

Cys Thr Ala Leu Leu Ala Glu Gly Ile Thr Trp Val Leu Val Tyr Arg

20 25 30

Thr Asp Lys Tyr Lys Arg Leu Lys Ala Glu Val Glu Lys Gln Ser Lys
 35 40 45
 Lys Leu Glu Lys Lys Lys Glu Thr Ile Thr Glu Ser Ala Gly Arg Gln
 50 55 60
 Gln Lys Lys Lys Ile Glu Arg Gln Glu Glu Lys Leu Lys Asn Asn Asn
 65 70 75 80
 Arg Asp Leu Ser Met Val Arg Met Lys Ser Met Phe Ala Ile Gly Phe
 85 90 95
 Cys Phe Thr Ala Leu Met Gly Met Phe Asn Ser Ile Phe Asp Gly Arg
 100 105 110
 Val Val Ala Lys Leu Pro Phe Thr Pro Leu Ser Tyr Ile Gln Gly Leu
 115 120 125
 Ser His Arg Asn Leu Leu Gly Asp Asp Thr Thr Asp Cys Ser Phe Ile
 130 135 140
 Phe Leu Tyr Ile Leu Cys Thr Met Ser Ile Arg Gln Asn Ile Gln Lys
 145 150 155 160
 Ile Leu Gly Leu Ala Pro Ser Arg Ala Ala Thr Lys Gln Ala Gly Gly
 165 170 175
 Phe Leu Gly Pro Pro Pro Pro Ser Gly Lys Phe Ser
 180 185

<210> 6

<211> 1300

<212> DNA

<213> Homo sapiens

<400> 6

tactgactcg aggccaaagaa ttccggcacga ggcaattttt aattttttgtt aatatcaaca 60
 gcaaaagcct agtgcattgg gagatgtgca acctccctga aaatcttttc tgtttctgga 120
 gtacttcagg ggtggcctct ggccccagag cctttgccac agtgcctcca ccagccccc 180
 cctcatccgt ctgtttgcag agcctcatct acaggtcccc acgctgcctt ctttactcac 240
 tctgcgcttg gccgttttgc tatttggctt agtctacatt gggcggaagt ctgtgtgcac 300
 agagtgggtg ttctctcgag ccccttccac tcagagggcc acaccagcg atgccagtga 360
 aggtggcaca gcctctcttc agtttctect gactgtgac tcactggggt agaattcccc 420
 tgagagaatt cctcactca cggctccctt tgccagagtc agttcaatca ggtctgatgt 480
 gagcaattta cacacttgtc tcagaaaagtc cctcagggtt tgtagaggac tgcagggggg 540
 catccgctgc agactcagcc tttctctgca gccatcctgc agtgggggtg agcgggcaca 600
 ggctgagaac tgctcttggg tgggtggaagc aggtgtcacg gtgcaagtct cccctgcac 660
 cctccccca gcttgagccg tgtcaccccc ctctccctcc agcatgggccc tgtgtctcag 720
 gctctctgga aggtggccct gcccgggacc ctcttgacag tgtcctggtt tgacttggaa 780
 ctatagtgcc atctttccag gctttgggtg cccaagagca gtctgggtgg atggaagtgg 840
 ctgtcccttc ctctccagcc cctgcccacc cactgggtgga ggtgctaact agcaggggag 900
 tggcatagga tgggagctgg gcgtgaggtg cttgggggtcc attctttgtc cctcagcttc 960
 tcagagtccg gccagccctt gtgttccctg gcccacact ttctctctcc ccactgcagt 1020
 gaggcaatag tccgggggtg ggctggcct ccctgccctg attggggact caggaggtga 1080
 ggctggggg gcttctgccc cctccttgc ccactgcct gcccggggc agcacgggag 1140
 ggagagcagg gtgagcacgc ttgttggtt cagatgcact ttctgcttgc attgccgtat 1200
 ctgtgcgttc cttcatctg gtcttggtt tatggaacac catgttttta gcatgttttt 1260
 aaataaaaac ggataaagtg tcaaaaaaaa aaaaaaaaaa 1300

<210> 7
 <211> 62
 <212> PRT
 <213> Homo sapiens

<400> 7
 Met Cys Asn Leu Pro Glu Asn Leu Phe Cys Phe Trp Ser Thr Ser Gly
 1 5 10 15
 Val Ala Ser Gly Pro Arg Ala Phe Ala Thr Val Leu Pro Pro Ala Pro
 20 25 30
 Thr Ser Ser Val Cys Leu Gln Ser Leu Ile Tyr Arg Ser Pro Arg Cys
 35 40 45
 Leu Leu Tyr Ser Leu Cys Ala Trp Pro Phe Cys Tyr Leu Ala
 50 55 60

<210> 8
 <211> 1330
 <212> DNA
 <213> Homo sapiens

<400> 8
 aagcttgcca cgaggaagc ccatccaggt catgtgctac gactatgaca atgacggggg 60
 ccatgacttc atcggcgagt tccagacctc agtgtcacag atgtgtgagg ctcgagacag 120
 cgtcccgctg gagttcgagt gcatcaaccc caagaagcag aggaagaaga agaactataa 180
 aaactcgggc atcatcatcc tgcgacctg caagataaac cgagactact ccttccttga 240
 ctacatcctg ggaggctgcc agctcatgtt caccgttga atagacttta cagcctccaa 300
 cgggaatccc ctgcaccctt cctctttgca ctatatcaac cctatgggca ccaacgaata 360
 tctgtcggcc atctgggctg ttgggcagat cattcaggac tacgacagtg ataagatgtt 420
 tccagctctg ggattcgggg ccagttacc ccagactgg aagtctccca tgagtttgcc 480
 atcaacttca accccaccaa ccccttctgc tcaggtgtgg atggtattgc ccaggcgta 540
 tcagcttgcc tgccccacat ccgcttctac ggtcctacca atttctcccc catcgtaac 600
 cacgtggccc ggtttgccgc ccaggccaca caacagcgga cggccacgca gtacttcac 660
 ctccatcatca tcacggacgg ggatcatcagt gacatggagg agacacggca tgccgtgggtg 720
 caggcttcca agctgccccat gtccatcatc atcgtgggcg tgggcaatgc ggacttcgct 780
 gccatggagt tccatggatg ggacagccgc atgctgcgct cccacacggg ggaggaggca 840
 gcccgcgata ttgtgcagtt cgttcccttt cgagagtcc gcaacgcagc aaaagagacc 900
 ttggccaaag ctgtgtgtgc ggagctgccc caacaagttg tgcagtattt caagcataaa 960
 aacctgcccc ccaccaactc ggagcccgcc tgagctccag tgcccagcag cagcatgtca 1020
 gctgagccct ctgccctccc ccaggaacat gcacgctcac tctgcttcc tgtgggtggc 1080
 ctttttttac cgatccccct ttttattttt tacaaccgga cctccacccc caacttctc 1140
 cagcccgagt gggcttccct ttgtggagtc aactgttgat gcttccaggc caaactggct 1200
 tctctctctc ctctcccccac ctttgccatt cttaagtatt gaatgtactt tgtataattt 1260
 tagtgggaatt gttattgaga ataaaatttt tacaatcata aaaaaaaaaa aaaaaaaaaa 1320
 aaaaaaaaaa 1330

<210> 9
 <211> 423
 <212> PRT
 <213> Homo sapiens

<400> 9
 Met Cys Tyr Asp Tyr Asp Asn Asp Gly Gly His Asp Phe Ile Gly Glu
 1 5 10 15
 Phe Gln Thr Ser Val Ser Gln Met Cys Glu Ala Arg Asp Ser Val Pro
 20 25 30

Leu Glu Phe Glu Cys Ile Asn Pro Lys Lys Gln Arg Lys Lys Lys Asn
 35 40 45
 Tyr Lys Asn Ser Gly Ile Ile Ile Leu Arg Ser Cys Lys Ile Asn Arg
 50 55 60
 Asp Tyr Ser Phe Leu Asp Tyr Ile Leu Gly Gly Cys Gln Leu Met Phe
 65 70 75 80
 Thr Val Gly Ile Asp Phe Thr Ala Ser Asn Gly Asn Pro Leu Asp Pro
 85 90 95
 Ser Ser Leu His Tyr Ile Asn Pro Met Gly Thr Asn Glu Tyr Leu Ser
 100 105 110
 Ala Ile Trp Ala Val Gly Gln Ile Ile Gln Asp Tyr Asp Ser Asp Lys
 115 120 125
 Met Phe Pro Ala Leu Gly Phe Gly Ala Gln Leu Pro Pro Asp Trp Lys
 130 135 140
 Ser Pro Met Ser Leu Pro Ser Thr Ser Thr Pro Pro Thr Pro Ser Ala
 145 150 155 160
 Gln Val Trp Met Val Leu Pro Arg Arg Thr Gln Leu Ala Cys Pro Thr
 165 170 175
 Ser Ala Ser Thr Val Leu Pro Ile Ser Pro Pro Ser Ser Thr Thr Trp
 180 185 190
 Pro Gly Leu Arg Pro Arg Pro His Asn Ser Gly Arg Pro Arg Ser Thr
 195 200 205
 Ser Ser Ser Ser Ser Ser Arg Thr Gly Ser Ser Val Thr Trp Arg Arg
 210 215 220
 His Gly Met Pro Trp Cys Arg Leu Pro Ser Cys Pro Cys Pro Ser Ser
 225 230 235 240
 Ser Trp Ala Trp Ala Met Arg Thr Ser Leu Pro Trp Ser Ser Trp Met
 245 250 255
 Gly Thr Ala Ala Cys Cys Ala Pro Thr Arg Gly Arg Arg Gln Pro Ala
 260 265 270
 Ile Leu Cys Ser Ser Phe Pro Phe Glu Ser Ser Ala Thr Gln Gln Lys
 275 280 285
 Arg Pro Trp Pro Lys Leu Cys Trp Arg Ser Cys Pro Asn Lys Leu Cys
 290 295 300
 Ser Ile Ser Ser Ile Lys Thr Cys Pro Pro Pro Thr Arg Ser Pro Pro
 305 310 315 320
 Glu Leu Gln Cys Pro Ala Ala Ala Cys Gln Leu Ser Leu Leu Pro Ser
 325 330 335
 Pro Arg Asn Met His Ala His Ser Ala Ser Leu Trp Val Ala Phe Phe
 340 345 350

Tyr Arg Ser Pro Phe Leu Phe Phe Thr Thr Gly Pro Pro Pro Pro Thr
 355 360 365
 Ser Ser Ser Pro Ala Gly Leu Pro Leu Leu Glu Ser Thr Val Asp Ala
 370 375 380
 Ser Arg Pro Asn Trp Leu Pro Leu Leu Leu Ser Pro Pro Leu Pro Phe
 385 390 395 400
 Leu Ser Ile Glu Cys Thr Leu Tyr Asn Phe Ser Gly Ile Val Ile Glu
 405 410 415
 Asn Lys Ile Phe Thr Ile Ile
 420

<210> 10
 <211> 1920
 <212> DNA
 <213> Homo sapiens

<400> 10
 aagcttggca cgagggcgga gacggcggag cgggcctttt ggcgtccact gcgcggctgc 60
 accctgcccc atcctgcccg gatcatgggc tgcggcagcc cgggagggat gctgctgctg 120
 cgggcccggc tgcttgccct ggctgctctc tgcctgctcc gggcgcccg ggctcgggct 180
 gcagcctgtg agcccgctcg catccccctg tgcaagtcctc tgcctgggaa catgactaag 240
 atgcccacc acccgacca cagcactcag gccaacgcca tctgggcat cgagcagttc 300
 gaaggctctg tgggcaccca ctgcagcccc gatctgctct tcttctctg tgccatgtac 360
 gcgcccctct gcaccattga cttccagcac gagcccatca agcctgtaa gtctgtgtgc 420
 gagcgggccc ggcagggctg tgagcccata ctcatcaagt accgcccactc gtggccggag 480
 aacctggcct gcgaggagct gccagtgtac gacagggcg tgtgcatctc tcccaggaggc 540
 atcgttactg cggacggagc tgattttcct atggattcta gtaacggaaa ctgtagaggg 600
 gcaagcagtg aacgctgtaa atgtaagcct attagagcta cacagaagac ctatttcgg 660
 aacaattaca actatgtcat tcgggctaaa gttaaagaga taaagactaa gtgccatgat 720
 gtgactgcag tagtgagggt gaaggagatt ctaaagtcct ctctggtaaa cattccacag 780
 gacactgtca acctctatac cagctctggc tgctctgccc ctccacttaa tgttaatgag 840
 gaatatatca tcattgggcta tgaagatgag gaacgttcca gattactctt ggtggaaggc 900
 tctatagctg agaagtggaa ggatcgactc ggtaaaaaag ttaagcgctg ggatatgaag 960
 cttcgctcac ttggactcag taaaagtgat tctagcaata gtgattccac tcagagtcag 1020
 aagtctggca ggaactcgaa cccccggcaa gcacgcaact aaatcccga atacaaaaag 1080
 taacacagtg gacttctat taagacttac ttgcattgct ggactagcaa aggaaaattg 1140
 cactattgca catcatattc tattgtttac tataaaaaatc atgtgataac tgattattac 1200
 ttctgtttct cttttggttt ctgcttctct cttctctcaa cccctttgta atggtttggg 1260
 ggcagactct taagtatat gtgagtttct tatttcta atcatgagaa aaactgttct 1320
 tttgcaataa taataaatta aacatgctgt taccagagcc tctttgctgg agtctccaga 1380
 tgtaattta cttctgcac cccaattggg aatgcaatat tggatgaaa gagaggtttc 1440
 tggatttcac agaaagctag atatgcctta aaacatactc tgccgatcta attacagcct 1500
 tatttttgta tgccttttg gcattctcct catgcttaga aagttccaaa tgtttataaa 1560
 ggtaaaatgg cagtttgaag tcaaatgtca cataggcaaa gcaatcaagc accaggaagt 1620
 gtttatgagg aaacaacacc caagatgaat tatttttgag actgtcagga agtaaaataa 1680
 ataggagctt aagaaagaac attttgcctg attgagaagc acaactgaaa ccagtagccg 1740
 ctggggtgtt aatggtagca ttcttctttt ggcaatacat ttgatttgt catgaatata 1800
 ttaatcagca ttagagaaat gaattataac tagacatctg ctgttatcac catagttttg 1860
 ttaatttgc ttccttttaa ataaacccat tggtgaaagt caaaaaaaaa aaaaaaaaaa 1920

<210> 11
 <211> 325
 <212> PRT
 <213> Homo sapiens

<400> 11

```

Met Val Cys Gly Ser Pro Gly Gly Met Leu Leu Leu Arg Ala Gly Leu
 1           5           10           15

Leu Ala Leu Ala Ala Leu Cys Leu Leu Arg Val Pro Gly Ala Arg Ala
          20           25           30

Ala Ala Cys Glu Pro Val Arg Ile Pro Leu Cys Lys Ser Leu Pro Trp
 35           40           45

Asn Met Thr Lys Met Pro Asn His Leu His His Ser Thr Gln Ala Asn
 50           55           60

Ala Ile Leu Ala Ile Glu Gln Phe Glu Gly Leu Leu Gly Thr His Cys
 65           70           75           80

Ser Pro Asp Leu Leu Phe Phe Leu Cys Ala Met Tyr Ala Pro Ile Cys
          85           90           95

Thr Ile Asp Phe Gln His Glu Pro Ile Lys Pro Cys Lys Ser Val Cys
100           105           110

Glu Arg Ala Arg Gln Gly Cys Glu Pro Ile Leu Ile Lys Tyr Arg His
115           120           125

Ser Trp Pro Glu Asn Leu Ala Cys Glu Glu Leu Pro Val Tyr Asp Arg
130           135           140

Gly Val Cys Ile Ser Pro Glu Ala Ile Val Thr Ala Asp Gly Ala Asp
145           150           155           160

Phe Pro Met Asp Ser Ser Asn Gly Asn Cys Arg Gly Ala Ser Ser Glu
165           170           175

Arg Cys Lys Cys Lys Pro Ile Arg Ala Thr Gln Lys Thr Tyr Phe Arg
180           185           190

Asn Asn Tyr Asn Tyr Val Ile Arg Ala Lys Val Lys Glu Ile Lys Thr
195           200           205

Lys Cys His Asp Val Thr Ala Val Val Glu Val Lys Glu Ile Leu Lys
210           215           220

Ser Ser Leu Val Asn Ile Pro Gln Asp Thr Val Asn Leu Tyr Thr Ser
225           230           235           240

Ser Gly Cys Leu Cys Pro Pro Leu Asn Val Asn Glu Glu Tyr Ile Ile
          245           250           255

Met Gly Tyr Glu Asp Glu Glu Arg Ser Arg Leu Leu Leu Val Glu Gly
260           265           270

Ser Ile Ala Glu Lys Trp Lys Asp Arg Leu Gly Lys Lys Val Lys Arg
275           280           285

Trp Asp Met Lys Leu Arg His Leu Gly Leu Ser Lys Ser Asp Ser Ser
290           295           300

Asn Ser Asp Ser Thr Gln Ser Gln Lys Ser Gly Arg Asn Ser Asn Pro

```

305

310

315

320

Arg Gln Ala Arg Asn
325

<210> 12

<211> 1469

<212> DNA

<213> Homo sapiens

<400> 12

gatagcttgg caccgaggctg ggaagtagag gtgttgtgct gagcggcgct cggcgaactg 60
tgtggaccgt ctgctgggac tccggccctg cgtccgctca gccccgtggc cccgcgcacc 120
tactgccatg gagacgcggc ctctgtctcg ggccacctgt ttgctgggct tcagtttctt 180
gtcctctgct atctcttctg atggacataa tgggcttggg aagggttttg gagatcatat 240
tcattggagg aactggaag atgggaagaa agaagcagct gccagtggac tgcccctgat 300
ggtgattatt cataaatcct ggtgtggagc ttgcaaagct ctaaagccca aatttgaga 360
atctacggaa atttcagaac tctcccataa tttgtttatg gtaaattctg aggatgaaga 420
ggaaccacaa gatgaagatt tcagccctga cgggggttat attccacgaa tcctttttct 480
ggatccagct ggcaaggtgc atcctgaaat catcaatgag aatggaaacc ccagctaca 540
gtatttttat gtcagtgccg agcaagtgtt tcaggggatg aaggaagctc aggaaggct 600
gacgggtgat gccttcagaa agaaacatct tgaagatgaa ttgtaacatg aatgtgcccc 660
ttctttcatc agagttagtg ttctggaagg aaagcagcag ggaagggaat attgaggaat 720
catctagaac aattaagccg accaggaaac ctcatctcta cctacactgg aaggagcgt 780
ctcactgtgg aagagtcttg ctaacagaag ctgggtctgca tgtttgtgga tccagcggag 840
agtggcagac ttctttctcc ttttccctct cacctaaatg tcaacttgct attgaatgta 900
aagaatgaaa cttcttgaca caaaacttga gccacttggg tgtttactcc tcgcacttaa 960
gtatttgagt cttttcccat ttctcccat tttactcacc ttagtggtga aaggagacta 1020
gtagcatctt ttctacaacg ttaaaattgc agaagtagct tatcattaaa aaacaacaac 1080
aacaacaata acaataaatc ctaagtgtaa atcagttatt ctacccctta ccaaggatat 1140
cagcctgttt ttctcctttt ttctcctggg aataattgtg ggcttcttcc caaatttcta 1200
cagcctcttt cctcttctca tgcttgagct tccctgtttg cacgcatgcy tgtgcaggac 1260
tggtgtgtg cttggactcg gctccagggt gaagcatgct ttcccttggt actgttgagg 1320
aaactcaaac cttcaagccc taggtgtagc catcttgtca agtcatcaac tgtatttttg 1380
tactggcatt aacaaaaaaa gagataaaat attgtaccat taaactttta taaaacttta 1440
aaaggaaaaa aaaaaaaaaa aaaaaaaaaa 1469

<210> 13

<211> 172

<212> PRT

<213> Homo sapiens

<400> 13

Met Glu Thr Arg Pro Arg Leu Gly Ala Thr Cys Leu Leu Gly Phe Ser
1 5 10 15
Phe Leu Leu Leu Val Ile Ser Ser Asp Gly His Asn Gly Leu Gly Lys
20 25 30
Gly Phe Gly Asp His Ile His Trp Arg Thr Leu Glu Asp Gly Lys Lys
35 40 45
Glu Ala Ala Ala Ser Gly Leu Pro Leu Met Val Ile Ile His Lys Ser
50 55 60
Trp Cys Gly Ala Cys Lys Ala Leu Lys Pro Lys Phe Ala Glu Ser Thr
65 70 75 80
Glu Ile Ser Glu Leu Ser His Asn Phe Val Met Val Asn Leu Glu Asp

	85		90		95	
Glu Glu Glu Pro Lys Asp Glu Asp Phe Ser Pro Asp Gly Gly Tyr Ile						
	100		105		110	
Pro Arg Ile Leu Phe Leu Asp Pro Ser Gly Lys Val His Pro Glu Ile						
	115		120		125	
Ile Asn Glu Asn Gly Asn Pro Ser Tyr Lys Tyr Phe Tyr Val Ser Ala						
	130		135		140	
Glu Gln Val Val Gln Gly Met Lys Glu Ala Gln Glu Arg Leu Thr Gly						
145		150		155		160
Asp Ala Phe Arg Lys Lys His Leu Glu Asp Glu Leu						
	165		170			

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17469

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/47, 14/00, 7/00; C12N 15/10, 15/11, 15/12

US CL : 530/350, 300; 536/23.1, 23.5; 435/69.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 300; 536/23.1, 23.5; 435/69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, Genbank, Sequence Databases (EMBL, PIR, SWISSPROT)
search terms: am207_li

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96/39486 A1 (HUMAN GENOME SCIENCES, INC.) 12 December 1996, Figure 1B, claim 13, and page 21.	1-3, 5
X	US 5,501,969 A (HASTINGS ET AL.) 26 March 1996, SEQ ID NO:12, HumcatD of Figure 2.	3
Y	HILLIER ET AL. GenBank Database, National Library of Medicine, Bethesda, Maryland USA, Accession Number R52804, yg99g12.rl Homo sapiens cDNA clone 41757 5', 18 May 1995.	1-5
Y	HILLIER ET AL. GenBank Database, National Library of Medicine, Bethesda, Maryland USA, Accession Number R96245, yq36a02.rl Homo sapiens cDNA clone 197834 5', 11 September 1995.	1-5

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 13 NOVEMBER 1998	Date of mailing of the international search report 17 DEC 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer CLAIRE M. KAUFMAN Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17469

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LENNON ET AL. The I.M.A.G.E. consortium: An integrated molecular analysis of genomes and their expression. Genomics. 01 April 1996, Vol. 33, pages 151-152, entire document.	1-5
Y	WO 94/01548 A2 (MEDICAL RESEARCH COUNCIL) 20 January 1994, pages 10 and 11.	1-5
Y	THOMSEN ET AL. Applications of insect cell gene expression in pharmaceutical research. Bioprocess Technol. 1993, Vol. 17, pages 105-138, especially page 117-123.	1-5

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/17469

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/17469

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-5, drawn to a protein encoded by the DNA insert of clone am207_li and composition.

Group II, claim(s) 6-7, drawn to a protein encoded by the DNA insert of clone am910_li.

Group III, claim(s) 8-9, drawn to protein encoded by the DNA insert of clone ar54_li.

Group IV, claim(s) 10-11, drawn to a protein encoded by the DNA insert of clone L200_li.

Group V, claim(s) 12-13, drawn to a protein encoded by the DNA insert of clone wa129_21.

Group VI, claims 14-15, drawn to a protein encoded by the DNA insert of clone wa154_3i.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Because each protein is structurally unrelated and has not been assigned a distinct function, and the encoding DNAs are likewise structurally different, so the proteins do not share a special technical feature.